figitumumab + cisplatin + etoposide

A combination regimen consisting of **figitumumab**, a fully human IgG2 monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R); **cisplatin**, a platinum-based chemotherapy; and **etoposide**, a topoisomerase II inhibitor. Figitumumab blocks IGF-1R-mediated signal transduction promoting antitumor activity, while cisplatin causes DNA crosslinking leading to apoptosis and etoposide inhibits DNA synthesis through topoisomerase II inhibition. This combination was investigated for antineoplastic effects in solid tumors, especially small cell lung cancer, but clinical development was discontinued. Figitumumab was being developed by Pfizer, but development ceased in 2011[3][5].